Pharma

Quintiles to help Samsung expand into drug manufacturing

Quintiles is partnering with Samsung in an initiative that brings the diversified South Korean conglomerate into the pharmaceutical manufacturing business. Quintiles has a $30 million stake in Samsung’s $266 million plan.

Quintiles is partnering with Samsung Group on a $266 million initiative to bring the South Korean conglomerate into the drug manufacturing business.

Durham, North Carolina-based Quintiles provides an array of services for pharmaceutical companes and it is the largest clinical research organization in the industry. Quintiles spokesman Phil Bridges said that the company’s involvement with Samsung is a $30 million stake in the effort.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Bridges said Quintiles can help Samsung get into what for the South Korean conglomerate is a completely new market in life sciences. Besides holding a minority stake in Samsung’s biopharmaceuticals initiative, Quintiles will also offer Samsung its pharmaceuticals expertise. Quintiles has had a presence in South Korea since 2000 and currently employs about 100 people there.

“As part of the strategic partnership, Quintiles will provide clinical development and consulting services to Samsung as required,” Bridges said.

Samsung, a diversified company whose businesses include consumer electronics, insurance and shipbuilding, announced last year plans to add biopharmaceutical manufacturing to its portfolio. Samsung said that it plans for a South Korean factory that will produce biopharmaceutical drugs to treat cancer and arthritis. Ground breaking is scheduled for May and operations are expected to launch in April 2013.

Quintiles has established several partnerships with pharmaceutical companies, such as Eli Lilly (NYSE:LLY), that go beyond the traditional CRO role of providing outsourced pharmaceutical services. But Bridges said it is unusual for Quintiles to be working with a company such as Samsung that is not already a pharmaceuticals player. While Bridges would not say that this is the only partnership Quintiles has outside the life sciences space, he said the Samsung arrangement “is pretty unique for us.”